[The efficacy of treatment with the tranquilizer tranxene in elderly persons with psychoemotional disorders against a background of initial and moderately pronounced atherosclerotic circulatory encephalopathy].
Therapeutic effects of a minor tranquilizer (from the group of benzodiazepines) tranxene were studied in patients presenting with psychoemotional disorders in the presence of the onset moderately severe atherosclerotic dyscirculatory encephalopathy. The patients derived apparent benefit from the treatment administered as per subjective as well as objective evidence: the levels of hypochondria, depression, hysterioidness, psychoasthenicity, got significantly decreased, with positive changes being recordable in EEG as well as REG. The results obtained allow tranxene to be recommended for use in geriatric practice in patients presenting with cerebral atherosclerosis accompanied by psychoemotional disorders.
Grebel'nik
V I
VI
D000342:Affective Symptoms / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D000368:Aged; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D003009:Clorazepate Dipotassium / Q000627:therapeutic use*; D004341:Drug Evaluation; D004569:Electroencephalography / Q000187:drug effects; D005260:Female; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000150:complications* / Q000175:diagnosis / Q000523:psychology; D008950:MMPI; D008297:Male; D008875:Middle Aged
D014151:Anti-Anxiety Agents; D003009:Clorazepate Dipotassium